Reading between the lines
Direct-to-consumer advertising of genetic testing in the USA
Bibliographic Data
| ID | 3972461 |
|---|---|
| Authors | Sara Chandros Hull (0000-0001-8742-4997, National Human Genome Research Institute, corresponding author), Kiran Prasad |
| Year | 2001 |
| Volume | 9 |
| Issue | 18 |
| Pages | 44-48 |
| Publication date | 2001-01-01 |
| Open Access | No |
| Type | ARTICLE |
| Venue | Reproductive Health Matters (JOURNAL) |
| Journal identifiers | ISSN: 0968-8080 • E-ISSN: 1460-9576 |
| Publisher | Informa UK Limited (PUBLISHER • GB) |
| DOI | 10.1016/s0968-8080(01)90089-8 |
| PMID | 11765398 |
| OpenAlex | W2058445922 |
| Language | EN |
| Citations received | 3 |
| References cited | 18 |
This article critiques an advertisement in a theatre playbill by a bio-technology company for its commercial test for the BRCA1 and BRCA2 genetic mutation, which may indicate a higher risk for breast and ovarian cancer. The advertisement targets a vulnerable audience attending a play about one woman's isolated and painful death from ovarian cancer. It promotes a product with incomplete and at times incorrect information, and it misguides women by suggesting that they contact the company directly about this test, rather than encouraging them to talk to their health care providers about genetic testing and their personal risk of breast cancer. In an era in which more genetic tests will be integrated into clinical practice, we can expect an increase in direct-to-consumer marketing for such tests. This advertisement is an example of what we need to be on guard against
Advertising · Biology · Breast cancer · Business · Cancer · Genetic testing · Ovarian cancer · Political science · BRCA gene mutations in cancer · Computer Science · Law · Medicine · Nutrition, Genetics, and Disease · Internal Medicine · Marketing
| Citations per year | 0.15 |
|---|---|
| Citation span | 2006 - 2025 (20) |
| Highly cited | No |